UBS analyst AJ Rice raised the firm’s price target on Acadia Healthcare (ACHC) to $31 from $27 and keeps a Buy rating on the shares. Volume growth in Q1 may be uneven due to winter storms across January through March, with hospitals reporting short-term disruptions but expecting limited full-quarter impact as procedures are often rescheduled, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare Refreshes Board With Finance Veteran Appointment
- Acadia Healthcare price target raised to $20 from $14 at Barclays
- Acadia Healthcare Balances Growth Ambition With Rising Risks
- Acadia Healthcare’s Stock Volatility Spurs Litigation Risk and Challenges in Talent Retention
- Acadia Healthcare price target raised to $26 from $20 at Deutsche Bank